Endologix, Inc. (ELGXQ)
| Market Cap | 411,076 |
| Revenue (ttm) | 124.88M |
| Net Income (ttm) | -59.80M |
| Shares Out | 20.72M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Oct 2, 2020 |
| Last Price | $0.0199 |
| Previous Close | $0.0199 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.0100 - 0.0289 |
| Day's Volume | 0 |
| 52-Week Range | 0.0100 - 0.1340 |
News
IRVINE, Calif.--(BUSINESS WIRE)-- #AAA--Endologix has launched the ALTO™ Abdominal Stent Graft System in Europe for the treatment of patients with abdominal aortic aneurysm (AAA)
IRVINE, Calif.--(BUSINESS WIRE)--Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc.
Endologix (ELGXQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVINE, Calif.--(BUSINESS WIRE)--Transforming the treatment of aortic disorders, Endologix® Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S.
Shares of Endologix, Inc. (NASDAQ: ELGX), a manufacturer of medical devices for the treatment of aortic disorder, are moving to the downside Monday.
Shares of Endologix Inc. ELGX, -2.77% plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to...
Endologix, Inc. (ELGX) CEO John Onopchenko on Q1 2020 Results - Earnings Call Transcript
Endologix (ELGX) delivered earnings and revenue surprises of -19.40% and 0.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to Endologix (ELGX) stock based on the movements in the options market lately.
Endologix, Inc. (ELGX) CEO John Onopchenko on Q4 2019 Results - Earnings Call Transcript
Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix (ELGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endologix, Inc. (ELGX) CEO John Onopchenko on Q3 2019 Results - Earnings Call Transcript
Endologix (ELGX) delivered earnings and revenue surprises of 15.63% and 1.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endologix's (ELGX) CEO John Onopchenko on Q2 2019 Results - Earnings Call Transcript
Endologix (ELGX) delivered earnings and revenue surprises of 53.75% and 0.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor in Endologix, Inc. (ELGX).
Endologix's (ELGX) CEO John Onopchenko on Q1 2019 Results - Earnings Call Transcript
Endologix (ELGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
About ELGXQ
Endologix develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EV... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 20, 1996 |
| CEO John Onopchenko | Employees 488 |
| Stock Exchange OTCMKTS | Ticker Symbol ELGXQ |
Financial Performance
In 2019, Endologix's revenue was $143.37 million, a decrease of -8.37% compared to the previous year's $156.47 million. Losses were -$64.76 million, -18.76% less than in 2018.